Tremelimumab AstraZeneca
Analogs of Tremelimumab AstraZeneca
Find cheaper analogs and generic equivalents for Tremelimumab AstraZeneca.
Active Ingredient: tremelimumab
Product Overview
About Tremelimumab AstraZeneca
Tremelimumab AstraZeneca was granted marketing authorisation in the EU on 20 February 2023 for the treatment of metastatic non-small cell lung cancer (NSCLC). The marketing authorisation was initially valid for a 5-year period.
What it is used for
Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
How it is used
Information on how to use Tremelimumab AstraZeneca is not available in the provided facts.
How it works
Information on how Tremelimumab AstraZeneca works is not available in the provided facts.
Active substance: Tremelimumab AstraZeneca contains the same active substance as Imjudo.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
